Thema: US87184Q2066
SYRS, US87184Q2066
trading-643722_1920.jpg - Foto: THN
Syros Pharmaceuticals stock remains tied to Nasdaq delisting process
Syros Pharmaceuticals stock remains tied to the company's voluntary Nasdaq delisting process. Webull says the firm is no longer engaged in business activities.
ad-hoc-news.de, heute 00:21 Uhr
SYRS, US87184Q2066
Syros Pharmaceuticals stock: Next results date is October ...
The next report date is October 29, 2026. Syros Pharmaceuticals stock has 68 employees and develops gene-expression medicines.
ad-hoc-news.de, 24.10.26 00:21 Uhr
SYRS, US87184Q2066
Syros Pharmaceuticals has 68 employees: what it means for ...
Syros Pharmaceuticals lists a voluntary Nasdaq delisting and a gene-control pipeline. Its profile names 68 employees and fiscal year-end 2024.
ad-hoc-news.de, 14.10.26 00:05 Uhr
SYRS, US87184Q2066
Syros Pharmaceuticals stock carries a delisting legacy
Syros Pharmaceuticals stock is tied to a February 28, 2025 Nasdaq delisting decision. The company planned March filings as it shifted into a wind-down.
ad-hoc-news.de, 07.10.26 06:29 Uhr
SYRS, US87184Q2066
Syros approves wind-down: what it means for Syros Pharmaceuticals ...
Syros approved a wind-down on February 28, 2025. Syros Pharmaceuticals stock was USD 0.0004 on September 11, 2026, below USD 0.0200.
ad-hoc-news.de, 06.10.26 05:36 Uhr
SYRS, US87184Q2066
Syros Pharmaceuticals stock trades at USD 0.0004 after delisting ...
